SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Jan 6, 2020
Aptose Biosciences Inc. (CIK 0000882361)
Date: Jan. 6, 2020 · CIK: 0000882361 · Accession: 0000000000-20-000087
AI Filing Summary & Sentiment
File numbers found in text: 333-235730
Letter
January 6, 2020 Gregory K. Chow Chief Financial Officer Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 Re:Aptose Biosciences Inc. Registration Statement on Form S-3 Filed December 27, 2019 File No. 333-235730 Dear Mr. Chow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel M. Miller, Esq.
Show Raw Text
January 6, 2020
Gregory K. Chow
Chief Financial Officer
Aptose Biosciences Inc.
251 Consumers Road, Suite 1105
Toronto, Ontario, Canada M2J 4R3
Re:Aptose Biosciences Inc.
Registration Statement on Form S-3
Filed December 27, 2019
File No. 333-235730
Dear Mr. Chow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel M. Miller, Esq.